A Phase 2 interventional study of Centanafadine in Attention Deficit Hyperactivity Disorder, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 1 site in United States. Open to participants aged 9 Years to 12 Years. Per ClinicalTrials.gov, last updated 2023-01-13.
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing centanafadine in Attention Deficit Disorder with Hyperactivity — 5 open to participants now, 5 under way, 5 of them phase 3. centanafadine · Attention Deficit Disorder with Hyperactivity.
Among the 20 studies testing centanafadine in Attention Deficit Disorder with Hyperactivity, this one is the 20th largest by enrollment, is one of 4 that started in 2019, is the only one in phase 2, and was the 6th registered.
1,817 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 295 are open to participants now.
Browse Attention Deficit Disorder with Hyperactivity studies →5 of the 20 studies testing centanafadine in Attention Deficit Disorder with Hyperactivity are open now, in 2 countries. Recruiting first, the newest first:
Otsuka Pharmaceutical Development & Commercialization, Inc. · Sites in United States
Ages 18–65
Otsuka Pharmaceutical Co., Ltd. · Sites in Japan
Ages 6–17
Otsuka Pharmaceutical Co., Ltd. · Sites in Japan
Ages 6–17
Otsuka Pharmaceutical Co., Ltd. · Sites in Japan
Ages 18–55
Otsuka Pharmaceutical Co., Ltd. · Sites in Japan
Ages 18–55
By country, each count listing its studies:
centanafadine: first FDA approval 2026 (SIMTRIYO). What it is approved for, and how studies give it, is on its page →
Of the 201 Attention Deficit Disorder with Hyperactivity studies recruiting now, 27 (13%) set no upper age limit and 169 (84%) stop at 75 or younger; 141 take children under 18; 55 take healthy volunteers.
This study: 9 Years to 12 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 3 · Phase 3 12
First in 2014; this study’s year is marked. 4 started in 2019.
This study's enrollment of 13 is below the median of 71 across 1,437 interventional studies indexed under Attention Deficit Disorder with Hyperactivity.
Median enrollment 180 across the 20 interventional studies. Of the 15 that completed or were terminated, 4 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 20 have an industry lead sponsor. The 2 most frequent:
This study is registered under Otsuka Pharmaceutical Development & Commercialization, Inc., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 19 are open to participants now.
Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.
25 studies in Attention Deficit Disorder with Hyperactivity by Otsuka Holdings Co., Ltd.: 5 open now, 5 under way, 5 of them phase 3. Of 20 finished, 8 (40%) have results posted.
Among the 25 studies in Attention Deficit Disorder with Hyperactivity by Otsuka Holdings Co., Ltd., this one is the 25th largest by enrollment, is one of 4 that started in 2019, is one of 5 in phase 2, and was the 11th registered.
Otsuka Holdings Co., Ltd.’s Attention Deficit Disorder with Hyperactivity studies by the year they started, since 2010.
3 of the studies testing centanafadine in Attention Deficit Disorder with Hyperactivity that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07759154Phase 3Otsuka Pharmaceutical Development & Commercialization, Inc.A Study to Test the Effects of Centanafadine in Adults With Attention-deficit/Hyperactivity Disorder and Emotional Dysregulation | 2027-05-27 |
| NCT07087327Phase 3Otsuka Pharmaceutical Co., Ltd.A Long-term Trial of EB-1020 in Pediatric Patients With ADHD | 2027-08 |
| NCT07086313Phase 3Otsuka Pharmaceutical Co., Ltd.A Trial to Evaluate the Efficacy and Safety of EB-1020 in Pediatric Patients With ADHD | 2027-08 |
Add all 3 to your calendar (.ics) → With an account.
Among the 20 studies testing centanafadine in Attention Deficit Disorder with Hyperactivity, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Otsuka Holdings Co., Ltd.’s 25 in Attention Deficit Disorder with Hyperactivity:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
With the pharmacokinetics (PK) of centanafadine currently being evaluated in adults. The PK of extended-release centanafadine may differ in children compared to adults due to physiological differences in the gastrointestinal tract. The information in this trial will support pediatric dose selection in future trials.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants who have any of the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants swallowed two capsules of centanafadine (one containing a 50-milligram \[mg\] dose as extended release beads and other containing a 5-mg dose as immediate-release \[IR\] beads), total dose of 55 mg, orally in the morning of Day 1 following a minimum 8-hour fast.
Drug: Centanafadine
Participants were administered centanafadine 55 mg, contents of 2 capsules (one containing a 50-mg dose as beads and other containing a 5-mg dose as IR beads) sprinkled on a tablespoon of applesauce, orally in the morning of Day 1 following a minimum 8-hour fast.
Drug: Centanafadine
Extended-release and immediate-release capsules.
Also known as: EB-1020
Pharmacokinetic (PK) Parameter: Maximum Plasma Concentration (Cmax) of Centanafadine
Time frame: 1, 2, 3, 4, 6, 8, 10,12 hours post dose on Day 1 and 22-26 hours post dose on Day 2
PK Parameter: Time to Maximum Plasma Concentration (Tmax) of Centanafadine
Time frame: 1, 2, 3, 4, 6, 8, 10,12 hours post dose on Day 1 and 22-26 hours post dose on Day 2
PK Parameter: Area Under Concentration-time Curve From Time 0 to 12 Hours Postdose (AUC0-12h) of Centanafadine
Time frame: 0 to 12 hours post dose on Day 1
Participants took part in the study at 2 investigative sites in the United States from 07 October 2019 to 21 December 2019.
| Milestone | Swallowed Capsules Cohort | Sprinkled Onto Applesauce Cohort |
|---|---|---|
| Started | 7 | 6 |
| Completed | 6 | 6 |
| Not completed | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 |
| nanograms per milliliter (ng/mL) | Swallowed Capsules Cohort | Sprinkled Onto Applesauce Cohort |
|---|---|---|
| Pharmacokinetic (PK) Parameter: Maximum Plasma Concentration (Cmax) of Centanafadine | 153 ± 51.4 | 129 ± 52.8 |
| hours (h) | Swallowed Capsules Cohort | Sprinkled Onto Applesauce Cohort |
|---|---|---|
| PK Parameter: Time to Maximum Plasma Concentration (Tmax) of Centanafadine | 3.03 (2.00 to 10.00) | 2.58 (1.03 to 6.00) |
| h*ng/mL | Swallowed Capsules Cohort | Sprinkled Onto Applesauce Cohort |
|---|---|---|
| PK Parameter: Area Under Concentration-time Curve From Time 0 to 12 Hours Postdose (AUC0-12h) of Centanafadine | 962 ± 320 | 828 ± 346 |
Collected over Screening up to last follow-up (approximately 30 days). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Swallowed Capsules Cohort | 0/7 (0%) | 0/7 (0%) | 1/7 (14.3%) |
| Sprinkled Onto Applesauce Cohort | 0/6 (0%) | 0/6 (0%) | 0/6 (0%) |
| Event | Swallowed Capsules Cohort | Sprinkled Onto Applesauce Cohort |
|---|---|---|
| Vessel Puncture Site BruiseGeneral disorders | 1/7 | 0/6 |
Enrolled analysis set included all participants who had eligibility to enroll in the trial based on screening process.
| Age, Continuous(years) | Swallowed Capsules Cohort | Sprinkled Onto Applesauce Cohort | Total |
|---|---|---|---|
| Mean | 10.6 ± 1.0 | 10.5 ± 1.4 | 10.5 ± 1.1 |
| Sex: Female, Male(Participants) | Swallowed Capsules Cohort | Sprinkled Onto Applesauce Cohort | Total |
|---|---|---|---|
| Female | 0 | 4 | 4 |
| Male | 7 | 2 | 9 |
| Ethnicity (NIH/OMB)(Participants) | Swallowed Capsules Cohort | Sprinkled Onto Applesauce Cohort | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 2 | 3 |
| Not Hispanic or Latino | 6 | 4 | 10 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Swallowed Capsules Cohort | Sprinkled Onto Applesauce Cohort | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 2 | 2 |
| White | 6 | 4 | 10 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article publication. There is no end date to the availability of the data.
Access criteria: Otsuka will share data on an Otsuka-owned remotely accessible data sharing platform with Python and R analytical software. Research requests should be directed to clinicaltransparency@Otsuka-us.com
Data sharing details ↗ · clinical-trials.otsuka.com
Ran from Oct 2019 to primary completion in Dec 2019, 2 months.
Results were first posted in Jan 2023, 3 years after primary completion. A results delay was requested in Nov 2020.
Of 24 industry-sponsored phase 2 interventional studies under Attention Deficit Disorder with Hyperactivity, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 14. This study's 2 months is below that.
Counting every sponsor, half of 40 studies reached it within 15 months; a quarter within 5 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Centanafadine
Attention Deficit Disorder with Hyperactivity →
Otsuka Pharmaceutical Development & Commercialization, Inc. →